Women with inflammatory bowel disease (IBD) might have an increased tendency to choose an elective abortion due to a fear that their fetus could be harmed by use of medications, disease flares during pregnancy or for genetic reasons. We examined the risk of elective abortions in women with ulcerative colitis (UC) and Crohn's disease (CD) compared to women without IBD.
Introduction
Reproduction issues related to ulcerative colitis (UC) and Crohn's disease (CD) are a matter of constant concern as these chronic diseases mainly occur during the patient's fertile years. 1 In pregnant women with inflammatory bowel disease (IBD), existing literature has mainly focused on the short-term adverse birth outcomes of intrauterine growth retardation, low birthweight, preterm birth, and congenital malformations. [2] [3] [4] [5] Evidence regarding whether pregnant women with IBD are prone to choose an elective abortion is very limited. This is highly relevant to examine, as it might reflect the extent to which women with IBD are so worried about the viability of their fetus that they choose to terminate a pregnancy. Pregnant women with IBD often have a dilemma because on one hand disease activity might harm their fetus and therefore flares should be avoided during pregnancy, [6] [7] [8] [9] and on the other hand the women are reluctant to take the medications to control disease activity because they feel it might harm their fetus. [8] [9] [10] [11] This fear of a potential harmful impact of medications during pregnancy is an ongoing issue, and several papers have addressed the controversies surrounding the fetal safety of medications for IBD during pregnancy. 8, 10, [12] [13] [14] [15] [16] Furthermore, pregnant women with IBD might also choose to terminate the pregnancy due to genetic reasons, i.e. due to a higher risk of IBD in their offspring.
Only a few descriptive studies have estimated the proportions of women with IBD who choose an elective abortion and varying proportions have been reported. Kanis et al found 0.5% elective abortions in 413 IBD pregnancies 17 , and Riis et al found 6.2 % elective abortions in 177 IBD pregnancies, 18 but these results were not compared to elective abortions in the background populations. In a large cohort study from Denmark, the proportions of elective abortions were much higher (approximately 13-15 %) but the focus of that paper was ectopic pregnancy, and not elective abortions. 19 A few other studies have examined abortions but did not distinguish between spontaneous and elective abortions. 20 
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To our knowledge, no studies have estimated the risk for elective abortion in women with IBD compared to women without IBD, especially taking into consideration the important impact of each woman's former number of live born children. By law, since 1973, all Danish women aged 18 or above are allowed to receive an elective abortion upon maternal request up until the end of the 12 th completed week of gestation. Based on data from Danish national registries, we estimated the risk for women with IBD to choose an elective abortion relative to women without IBD. Our outcome was elective abortion by maternal request up until the end of the 12th completed week of gestation.
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Materials and Methods
Study population and setting
This cohort study was based on Danish nationwide heath registries. For all women in Denmark, with a valid civil registration number and of child-bearing age (15-50 years), we obtained information on all pregnancy outcomes that was available in the National Patient Register (NPR) during the study period of 1 January 1996 until 31 December 2015. For all clinicians in Denmark it is mandatory by law to report diagnostic codes and procedures to the NPR. We thus obtained information on the following types of pregnancy outcomes: births, elective abortions, spontaneous abortions, abnormal pregnancy products, missed abortions, pregnancies without fetus, ectopic pregnancies, hydatiform moles. Women in the study population could contribute with more than one pregnancy. The basic population of all pregnancy outcomes has previously been described. 19 All citizens in Denmark (population approximately 5.6 million inhabitants, > 90% Caucasians) have equal and free access to the tax-supported health care system. Also, in Denmark all women aged 18 or more are allowed to receive an elective abortion up until the end of the 12th week of gestational age. For women under the age of 18 a parental consent is required. Elective abortions are covered by the public tax system and therefore free of charge for the woman.
Data on exposure, outcome and confounders
Since 1977 the NPR has recorded information on all discharges from Danish hospitals and since 1995 extended to include all outpatient visits and emergency room contacts. 21 Information in the NPR includes patients' civil registration numbers, hospital, department, dates of admission and discharge, procedures performed, and discharge diagnoses based on the International Classification of Diseases (ICD). From 1994 onwards the classification in the NPR has used the ICD 10, while the ICD 8 was used prior to 1994. Furthermore, records maintained in the NPR include information on all deliveries in Denmark, as well as miscarriage and all other pregnancy outcomes. Each Danish resident is assigned a unique civil registration number from The Central Personal Registration system (CPR) and is used in all Danish healthcare registries. 22 All tables in the NPR are unambiguously linked by using the civil registration number, and also information on vital status was obtained from the CPR.
To investigate differences of elective abortions in our study population depending on maternal IBD, we obtained for all women information on maternal UC or CD from the NPR, and identified for all pregnancies maternal IBD (UC or CD) on the date of conception. For UC the codes ICD-8 563.19; 569.04; ICD-10 DK51 and all subgroups (except for DK51.9 for unspecified disease) were used, and for CD the codes ICD-8 563.01; ICD-10 DK50 and all subgroups were used. We included ICD- Data on confounders were obtained from the NPR. The NPR allowed linkage of maternal age at the time of conception, and information on number of previous births with a live-born child and maternal co-morbidity according to Charlson index. 23 The Charlson co-morbidity index, covering 19 major disease categories weighted according to their prognostic impact, was calculated for each woman based on all disease diagnoses recorded in previous hospitalizations since 1977.
Comorbidity was grouped into the three categories: none (Charlson index 0), some (Charlson index 8 1-2), and high (Charlson index ≥3). Maternal age at time of conception was categorized into four age groups (15-19, 20-24, 25-34 , and 35-50 years). We estimated the date of conception for each pregnancy using, from the NPR, the available information on gestational age at the time of the end of pregnancy. The conception date was estimated by subtracting the gestational age from the date of the recorded end of pregnancy. The calendar period of conception date was divided into three groups (1996-2001, 2002-2008, and 2009-2015) . Furthermore, we estimated the maternal age at time of each conception based on information on the maternal birthday.
Exposed cohort
In our study population of all pregnancies, the exposed cohort comprised all pregnancies by women diagnosed with either UC or CD before the estimated date of conception. In case a diagnosis of both UC and CD was registered on the same woman, then we used the last diagnosis of either UC or CD before the conception date to determine whether she was categorized into either UC or CD.
Unexposed cohort
The unexposed cohort comprised all pregnancies of women without a diagnosis of either UC or CD at the time of conception.
Outcome
Elective abortion registered as a pregnancy outcome in the NPR was the outcome. The elective abortion was performed upon maternal request up until the end of the 12th completed week of gestation.
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A contingency table was constructed for the main study variables according to women with and without IBD who chose an elective abortion. Also, the yearly proportions of women with UC and CD, and those without IBD, who chose an elective abortion were calculated and visualized by figure presentation. In this study, the pregnancy was the observation unit. Logistic regression was used to estimate crude and adjusted odd ratio (OR) on elective abortions (with 95% confidence intervals [95% CI]) for each pregnancy in women with IBD relative to women without IBD. Using robust cluster analysis, the logistic regression model accounted for multiple pregnancies of the same woman. Adjustments included maternal age at the time of estimated conception, calendar period of conception, co-morbidity index, and number of prior births with a live-born child.
Stratified analyses were done according to type of maternal underlying disease, i.e. UC or CD.
In a sub-analysis we included also the unspecified code for UC (DK51.9).
In another sub-analysis we examined only elective abortions among first time pregnancies.
All analyses were conducted using Stata 13 software (StataCorp LP, College Station, TX, USA).
Ethical Considerations
The study was approved by the Danish Data Protection Agency (j.nr. 2014-41-3466). According to Danish law, there are no ethical approvals of register-based studies necessary.
Results
The overall prevalence of elective abortions among all pregnancy outcomes in women with UC and CD was 12.4% (898 elective abortions among 7,250 pregnancies) and 14.9% (978 elective abortions among 6,559 pregnancies), respectively; and for women without IBD the prevalence was 16 .9% (285,251 elective abortions among 1,691,857 pregnancies). The types of pregnancy outcomes in the study population are shown in Table 1 . Figure 1 shows the proportions of elective abortions by calendar year from 1 January 1996 for women with UC, CD, and without IBD. The fluctuations of the curves for UC and CD are much greater than the curve for those without IBD as the proportions of elective abortion in women with UC and CD are based on much lower numbers than the curve representing patients without IBD.
For all three cohorts, the figure shows a decreasing tendency for elective abortions throughout the study period. Furthermore, for all calendar years since 2000, the yearly proportions of women with UC or CD choosing an elective abortion have been less than the proportions of elective abortions in women without IBD. Table 2 shows the descriptive characteristics for the 898 elective abortions in women with UC, the 978 in women with CD, and the 285,251 in women without IBD. In all three cohorts, most women who chose an elective abortion were in the age group 25-34 years ( Table 2 ). The mean age at conception in women with UC who chose an elective abortion was 31.2 years (SD 6.7), and the corresponding mean age in women with CD was 29.3 (SD 6.8), and 27.9 (SD 7.3) in women without IBD. The median age at conception in women with UC who chose an elective abortion was For the majority of women with and without IBD who chose an elective abortion, there were no other maternal co-morbidities present (UC 86.7%, CD 80.6%, non-IBD 92.1%), Table 2 .
In women with IBD who chose an elective abortion, 44.6% had no prior live-born children, and the corresponding number in those without IBD was 56.6%. A total of 24.8% of women with UC who chose an elective abortion had two prior live-born children, and the corresponding proportion in women with CD was 19.8%, and in women without IBD 15.0% ( Table 2 ).
The duration of IBD at the time of elective abortion was evenly distributed (some women had a disease duration of < 1 year while others ≥ 8 years). For women with UC, 30.4% had a disease duration of ≥ 8 years, and the corresponding proportion was 28.8% in women with CD ( Table 2 ).
In women with UC, the mean duration of IBD preceding each elective abortion was 6.2 years (SD 5.8), and in women with CD the mean duration of IBD was 5.6 years (SD 4.7).
The overall number of pregnancy outcomes and elective abortions, and the crude and adjusted ORs for elective abortions, are shown in Table 3 . Stratified by type of underlying disease we found that for women with UC and CD, the adjusted ORs for elective abortions were 0.80 (95 % CI, 0.74-0.86) and 0.96 (95 % CI, 0.86-1.04), respectively ( Table 3 ).
In the sub-analysis where we included the unspecified code for UC (DK51.9) our results were unchanged.
In the sub-analysis using only first time pregnancies, our results were virtually unchanged (for women with IBD the adjusted OR was 0.83 (95% CI, 0.73-0.91)).
In this nationwide study, our data suggest that women with UC and CD were not more likely to choose an elective abortion compared to women without IBD; in fact they were less likely to choose an election abortion. These results are reassuring as they suggest that women with IBD are not so worried about a negative impact of their disease, or the medications used to treat it, that they would choose to terminate a pregnancy.
To our knowledge, this is the first study, based on nationwide data, analysing the risk of elective abortion in women with UC and CD. Earlier reports on the proportion of elective abortions in women with IBD have been based on case series, 17, 18 and the proportion of elective abortions also appears as descriptive numbers in a large Danish study reporting the risk of ectopic pregnancy (based on a similar data as this study). 19 The proportions of elective abortions across these few studies thus varies widely, from 0.5% -15.6%, [17] [18] [19] and the reason is related to several factors. First, compared to data from case series, data based on nationwide information give a much more precise 24 The precision and the validity of our results depend on the size of the study, accurate classification of exposure and the outcome data, and the ability to take into account the influence of confounders. According to these aspects, our study has several strengths. First, the results are based 13 on nationwide data and unselected study populations. The data from the health registries have a very high completeness and validity. Second, according to the exposure assessment (diagnoses of IBD), the completeness of diagnoses of UC and CD has been examined in a Danish studyshowing that of all patients with a confirmed diagnosis of UC or CD, 94% were included in the NPR. 25 In the NPR we thus had access to mandatory registration of UC and CD diagnoses from both hospitals and outpatient clinics. Furthermore, the overall validity of diagnosis of UC in the NPR was 94% and for CD 97% in patients diagnosed at specialized departments. 25 Third, regarding our outcome (elective abortion) the data have both very high completeness and validity as such data are registered in the medical birth registry and transferred to the NPR. 26, 27 As elective abortions are free of charge in Denmark and not stigmatized politically, our registers have a complete coverage of elective abortions across all sociodemographic geographies. 24 Also, our outcome data were obtained independently of the hypothesis examined and the exposure assessment, preventing differential misclassification of our outcome measurement. Fourth, we had information on several important confounders, including comorbidity, women's age at conception, calendar period, and number of prior births of a live-born child.
Our study also has limitations. We lacked information on each person's ethnicity and on socioeconomic data, factors that we cannot rule out might have an impact on our results. 24 However, it is not very likely that our results are severely confounded by such factors. First, the population in Denmark is homogeneous with >90% of citizens being Caucasians. Second, for socioeconomic status to exert a confounding effect this factor must be unequally distributed between those with IBD and no IBD, and in a recent review it was concluded that there was no clear association between socioeconomic status and IBD incidence or prevalence, with various literature showing a positive, negative or no association at all. 28 In our study it was impossible to have information on all thinkable underlying reasons that prompted the women to choose an elective 14 abortion, a condition that applied to both our exposed and unexposed cohorts. However, given all the different worries that pregnant women with and without IBD might have, we focused on whether women with IBD were more likely to choose an election abortion than women in general, i.e. regardless of the reasons for termination of the pregnancy.
In our study we had no information on medical therapies, but the value of such information would only be of limited interest for several reasons. First, in this study we did not look into the women's reasons for choosing an elective abortion. Second, if we had information on medications we would not know what kind of medications to focus on, as women in our exposed and unexposed cohorts would have been treated with numerous different groups of medications, and we would not know which groups of medications that might have caused worries, if any, for each individual.
Third, even if we had information on medication for our exposed cohorts of women with IBD, we would not know whether use of medication was associated with the decision to terminate a pregnancy. Fourth, and most importantly, if our study had revealed, that women with IBD were more likely to choose an elective abortion than women in general, the question regarding medication could have been relevant, but our study suggested the opposite, i.e. women with IBD were less likely to choose an elective abortion.
There have been many studies examining the safety of IBD medications during pregnancy, and of course an introduction of new medications on the market (such as biologics, licensed in Denmark in 1999) draws special attention to the fetal safety. The fetal safety of IBD medication is for several reasons a matter of constant interest, 29 and at present there is a large ongoing US-wide prospective study examining biologics, thiopurines and small molecule therapy during pregnancy (the PIANO study). The majority of evidence favors the safety of biologics such as infliximab, adalimumab and certolizumab pegol during pregnancy, although US and European guidelines differ as to when to stop infliximab and adalimumab during the pregnancy period. [30] [31] [32] There is still very 15 little safety data on compounds such as vedolizumab, ustekinemab, and small molecule therapies (tofacitinib and other Janus Kinase Inhibitors). Additionally, many women are still taking thiopurines which have been used for IBD for more than 50 years and have shown to be safe during pregnancy. 12, 16 Despite the plethora of studies on the most commonly used medications many patients are still very worried about the effect of these drugs during pregnancy. It is not unusual for a pregnant patient to tolerate a mild to moderate amount of IBD activity rather than take biologics or thiopurines during pregnancy. This scenario is quite common despite that it is generally agreed that increased disease activity has a greater negative impact upon a pregnancy outcome than most IBD medications used to treat it. 7, 9 In this paper, we examined whether women with IBD chose elective abortions more often than fertile women in general, and a similar question could be asked for other maternal chronic diseases that are common during the fertile years. Women with, for example, rheumatoid arthritis, thyroid disease, epilepsy, diabetes and multiple sclerosis have to struggle with similar questions to women with IBD, namely questions about a possible negative impact of their disease on the fetus, and the fear that the medications used to treat the disease might harm the fetus. There are no robust data on elective abortions when it comes to the most frequent diseases during the fertile years 33 , i.e., rheumatoid arthritis, thyroid disease, epilepsy, and diabetes. Only for patients with multiple sclerosis, one study (based on 303 patients) suggests a higher proportion of elective abortions than among controls. 34 The rationale behind this present study is that women with IBD might be so worried about the impact of their disease in general, possible genetic transfer of the disease to the fetus, negative impact of disease flares and medications, that they might choose the option of an elective abortion.
It is reassuring that pregnant Danish women with IBD are so confident with factors related to their disease that they do not choose an elective abortion with a higher frequency than the general 16 pregnant population. In fact our results suggest that women with IBD were less likely to choose an election abortion, compared to women without IBD, and this might indicate that pregnancies in women with IBD are desired and well-planned. We believe that our results can be generalized to western countries with similar legislation regarding elective abortions, and our result helps complete the overall picture related to reproductive outcomes in women with IBD.
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Shows the proportions of elective abortions by calendar year from January 1, 1996 for women with ulcerative colitis (UC), Crohn's disease (CD), and women without inflammatory bowel disease (non-IBD) 
